Retour sur lavenir.net
   AGEAS 67.300 € (-0,37 %)     PROXIMUS 6.540 € (-1,06 %)     BIOTALYS 3.075 € (+6,22 %)     SOLVAY 27.340 € (-0,29 %)     KBC 113.700 € (+0,93 %)     TUBIZE-FIN 195.300 € (-3,41 %)     UCB 227.700 € (-4,29 %)     ACKERMANS V.HAAREN 276.800 € (+1,32 %)     GBL 79.900 € (+0,38 %)     RECTICEL 9.960 € (+0,20 %)     KBC ANCORA 77.600 € (+0,78 %)     FAGRON 23.800 € (+0,63 %)     SYENSQO 56.550 € (+1,07 %)     ARGENX SE 670.000 € (-1,06 %)     MELEXIS 71.600 € (+0,70 %)     UMICORE 17.200 € (+0,82 %)     EKOPAK 4.710 € (-0,63 %)     D'IETEREN GROUP 176.200 € (-0,51 %)     AEDIFICA 72.900 € (-0,27 %)     WDP 23.740 € (-0,67 %)     BQUE NAT. BELGIQUE 396.000 € (+1,54 %)     AB INBEV 63.300 € (+1,09 %)     KINEPOLIS GROUP 30.450 € (0,00 %)     AZELIS GROUP 11.500 € (+2,50 %)     BARCO 9.505 € (+0,85 %)     XIOR 27.600 € (-0,36 %)     MONTEA 70.400 € (-0,56 %)     WHAT''S COOKING GP 142.500 € (+0,35 %)     ONWARD MEDICAL 2.850 € (-1,38 %)     ELIA GROUP 140.500 € (+0,79 %)     RETAIL ESTATES 69.200 € (+0,29 %)     CELYAD ONCOLOGY 0.310 € (+2,65 %)     BREDERODE 103.400 € (+0,39 %)     SOFINA 220.200 € (+0,09 %)     BPOST 1.860 € (+0,11 %)     EXMAR 10.750 € (+0,94 %)     COLRUYT 33.140 € (+0,36 %)     IBA 13.500 € (-0,88 %)     GIMV 48.250 € (+0,63 %)     COFINIMMO 85.400 € (-0,06 %)     DEME GROUP 188.200 € (+0,97 %)     BEKAERT 41.450 € (-1,54 %)     FLUXYS BELGIUM D 21.500 € (0,00 %)     SEQUANA MEDICAL 0.611 € (-3,02 %)     CENERGY 21.320 € (-2,20 %)     VAN DE VELDE 32.600 € (0,00 %)     TEXAF 43.800 € (0,00 %)     WERELDHAVE BELGIUM 53.400 € (-0,37 %)     WAREHOUSES ESTATES 42.600 € (-0,93 %)     CMB.TECH 11.360 € (+3,27 %)     CARE PROPERTY INV. 12.920 € (0,00 %)     ASCENCIO 50.300 € (+0,20 %)     VGP 90.100 € (-0,55 %)     VASTNED 30.050 € (+0,33 %)     SIPEF 100.200 € (+0,70 %)     HOME INVEST BE. 19.220 € (+0,31 %)     OXURION 0.004 € (-5,00 %)     TITAN S.A. 46.440 € (+0,22 %)     EVS BROADC.EQUIPM. 36.350 € (+0,41 %)     TINC 11.860 € (0,00 %)  
   EMEIS 14.980 € (+1,70 %)     FDJ UNITED 23.590 € (-6,94 %)     ATON 0.023 € (+13,59 %)     LOUIS HACHETTE 1.713 € (-0,70 %)     MONCEY (FIN.) NOM. 138.000 € (+0,73 %)     VIRIDIEN 148.700 € (-1,91 %)     COTY 2.020 € (-0,98 %)     AYVENS 10.960 € (+0,74 %)     LVMH 463.200 € (-0,91 %)     TOTALENERGIES 78.620 € (+2,36 %)     SPIE 48.840 € (+0,12 %)     CSG 19.756 € (-0,42 %)     THERACLION 0.527 € (+9,79 %)     ADYEN 971.200 € (+0,53 %)     PROSUS 41.085 € (+0,77 %)     L'OREAL 378.050 € (+1,14 %)     ASM INTERNATIONAL 836.600 € (0,00 %)     CREDIT AGRICOLE 17.295 € (+0,93 %)     AXA 41.030 € (+0,64 %)     SOCIETE GENERALE 70.870 € (+1,20 %)     OSE IMMUNO 4.350 € (+18,92 %)     AIRBUS 166.060 € (+0,30 %)     BNP PARIBAS ACT.A 90.690 € (+0,59 %)     ARTMARKET COM 2.930 € (+1,74 %)     RANDSTAD NV 24.960 € (+0,24 %)     BE SEMICONDUCTOR 239.900 € (-3,27 %)     NEXANS 149.300 € (+9,14 %)     CARREFOUR 16.700 € (+1,43 %)     KERING 244.750 € (+0,41 %)     THALES 230.400 € (-0,35 %)     CLARIANE 4.116 € (+0,39 %)     SAFRAN 274.500 € (+0,18 %)     SANOFI 79.230 € (+0,42 %)     DASSAULT AVIATION 290.400 € (-0,48 %)     MAUREL ET PROM 9.710 € (+2,43 %)     AIR LIQUIDE 180.160 € (-3,98 %)     ASML HOLDING 1 212.200 € (-0,03 %)     ING GROEP N.V. 24.065 € (+0,77 %)     WORLDLINE 0.285 € (+5,63 %)     HOPIUM 0.009 € (-8,60 %)     PROLOGUE 0.267 € (+3,89 %)     STELLANTIS NV 6.829 € (-0,19 %)     STMICROELECTRONICS 43.445 € (+2,51 %)     VOPAK 42.020 € (+2,14 %)     DANONE 66.880 € (+0,45 %)     ORANGE 17.570 € (+1,06 %)     UBISOFT ENTERTAIN 4.834 € (-2,74 %)     LHYFE 2.230 € (-2,62 %)     B.COM.PORTUGUES 0.890 € (+2,30 %)     IPSOS 35.180 € (+0,69 %)     DBV TECHNOLOGIES 3.528 € (+0,46 %)     2CRSI 39.000 € (-3,23 %)     SCHNEIDER ELECTRIC 275.200 € (+0,04 %)     MAGNUM 11.132 € (+0,16 %)     MICHELIN 31.930 € (-0,41 %)     ABN AMRO BANK N.V. 29.240 € (+0,65 %)     HEINEKEN 66.260 € (+0,64 %)     UNILEVER 49.030 € (-0,26 %)     FORVIA 10.285 € (+1,13 %)     VALLOUREC 25.200 € (+0,12 %)  
News Réglementées
28/04/2026 09:01

Original-Research: MLP SE (von NuWays AG): BUY

Original-Research: MLP SE - from NuWays AG

28.04.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to MLP SE

Company Name:MLP SE
ISIN:DE0006569908
 
Reason for the research:Update
Recommendation:BUY
Target price:EUR 12
Target price on sight of:12 months
Last rating change:
Analyst:Simon Keller

Planning pays dividends

We hosted a roadshow with MLP CEO Dr. Uwe Schroeder-Wildberg. Key takeaways confirm the equity story momentum: MLP combines a c. 5% dividend yield with continuously improving revenue visibility and tangible adj. earnings growth.
  • Client proposition centred on “peace of mind”. MLP’s model is built around long-term financial planning and stable, mostly fee-based, adviser relationships. This is relevant in a market where customers can easily compare single products such as Tagesgeld, neobank accounts or ETFs. MLP’s focus remains the full financial package: banking, insurance, wealth, old-age provision and financing, anchored in personal advice and a long-term customer relationship. This supports retention and cross-selling as clients move through life stages.
  • Earnings quality continues to improve. 72% of sales are already recurring. Wealth and property and casualty (P&C) insurance are the main recurring growth pillars, helped by savings plans, rising customer maturity and inflation-linked premium volumes in non-life insurance. This improves forecasting quality and lowers reliance on one-off product sales. Against this backdrop, performance fees are not the foundation: MLP includes only high-single-digit €m performance fees annually (c. 1% of sales) in its mid-term targets, compared to a seven-year average of c. € 23m. With c. 70% incremental EBIT margin, stronger performance fees would be upside. 2025 also offers a low comparable base (only c. € 11m).
  • Disintermediation risk looks manageable. Neobanks, ETFs and AI remain relevant competitive forces, especially on pricing. Still, human advice remains the single most trusted source of investment guidance (source: CFA Institute), supporting the relevance of MLP’s adviser-led model. MLP’s answer is to integrate digitalisation and AI into the advisory process, improving transparency, speed and adviser productivity while preserving the personal relationship.
  • AI is turning into an operating lever. MLP already uses AI in business-relevant processes, with cost control visible in 2025 (adj. EBIT margin up 0.1pp yoy, despite declining performance fees). In P&C, an AI-supported claims solution can handle claims in roughly 10 minutes. Simultaneously, an insurance contract-checking tool can analyse existing client contracts and generate counter-offers with better pricing, better service or both. This supports customer benefit, adviser efficiency and the broader digitalisation case.
  • Dividend case backed by growth and cash. The dividend (5% yield at current levels) remains well supported by MLP’s 50-70% payout target and an expected 14% adj. EBIT CAGR into 2028e (eNuW, in line with mid-term targets). Consequently, the sustainable dividend should grow going forward, further anchored by MLP’s ambition to maintain dividend continuity. In addition, € >80m net available cash after regulatory buffers leaves room for M&A, special dividends or buybacks. Yet, the cash buffer should be seen to maintain financial flexibility, rather than a near-term distribution trigger.
In sum, MLP remains a quality financial advisory platform with a rare combination of yield, earnings growth, recurring revenue visibility and balance-sheet quality. BUY, PT € 12, on Residual Income.
 

You can download the research here: mlp-se-2026-04-28-update-en-75ac1
For additional information visit our website: https://www.nuways-ag.com/research-feed

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2316202  28.04.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière